The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice

被引:29
|
作者
Burns, Ted M. [1 ]
机构
[1] Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA
来源
关键词
MG composite; myasthenia gravis; outcome measures; MGC; MG; MYCOPHENOLATE-MOFETIL; RECOMMENDATIONS; CYCLOSPORINE; RELIABILITY; VALIDATION; STANDARDS; IVIG;
D O I
10.1111/j.1749-6632.2012.06812.x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The myasthenia gravis composite (MGC) was constructed by selecting the best performing items from three commonly used, MG-specific scales. The response categories of the items were subsequently weighted for importance. The MGC, which takes less than five minutes to complete, is made up of three ocular, three bulbar, one respiratory, one neck, and two limb items. After its construction, the MGC was validated in an 11-center scale validity study. During the validation study, which included test-retest analysis, it was determined that a 3-point improvement in MGC score reliably indicates clinical improvement. A 3-point improvement in MGC also appears to be meaningful to the patient. Rasch analysis of the MGC confirmed that all 10 items belong and can be summed to provide a total score, and that the weights given to the response categories of the items are appropriate.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 50 条
  • [21] Thymus imaging in myasthenia gravis: The relevance in clinical practice
    Klimiec, Elzbieta
    Quirke, Mary
    Leite, Maria Isabel
    Hilton-Jones, David
    MUSCLE & NERVE, 2018, 58 (01) : 153 - 156
  • [22] Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice
    Katyal, Nakul
    Govindarajan, Raghav
    Goyal, Neelam
    Muley, Suraj
    Muppidi, Srikanth
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [23] Use of Continuous Glucose Monitoring as an Outcome Measure in Clinical Trials
    Beck, Roy W.
    Calhoun, Peter
    Kollman, Craig
    DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (10) : 877 - 882
  • [24] IMAGING Use of MRI as an outcome measure in clinical trials in RA
    van der Helm-van Mil, Annette H. M.
    NATURE REVIEWS RHEUMATOLOGY, 2012, 8 (11) : 643 - 644
  • [25] Comparative effectiveness clinical trials to advance treatment of myasthenia gravis
    Guptill, Jeffrey T.
    Raja, Shruti
    Sanders, Donald B.
    Narayanaswami, Pushpa
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2018, 1413 (01) : 69 - 75
  • [26] Clinical-epidemiologic aspects of myasthenia gravis (MG) in Georgia
    Khizanishvili, N.
    Kvirkvelia, N.
    Shakarishvili, R. R.
    Beridze, M.
    Mikava, N.
    Jibladze, M.
    Nikolaishvili, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 330 - 330
  • [27] Myasthenia gravis: Historical achievements and the "golden age" of clinical trials
    Nguyen-Cao, Tam M.
    Gelinas, Deborah
    Griffin, Rhonda
    Mondou, Elsa
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 406
  • [28] Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease
    Cleanthous, Sophie
    Mork, Ann-Christin
    Regnault, Antoine
    Cano, Stefan
    Kaminski, Henry J.
    Morel, Thomas
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [29] Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease
    Sophie Cleanthous
    Ann-Christin Mork
    Antoine Regnault
    Stefan Cano
    Henry J. Kaminski
    Thomas Morel
    Orphanet Journal of Rare Diseases, 16
  • [30] Predictors of clinical outcome following extended thymectomy in myasthenia gravis
    Özdemir, N
    Kara, M
    Dikmen, E
    Nadir, A
    Akal, M
    Yücemen, N
    Yavuzer, S
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2003, 23 (02) : 233 - 237